Precision Medicine in Childhood and Young Person (TYA) Cancer Hype or Hope?
The Trustees of CwC UK are keen to make a major contribution to this technology in the UK by funding research and professional meetings. This meeting is primarily about higher precision diagnosis and treatment; our 2018 meeting next year will focus on causal factors. Progress in molecular and cellular biotechnologies has heralded the advent of an era of precision cancer medicine in which real time use of molecular genetics, proteomics and phenomics can be used for better diagnosis and hence deliver more effective, less toxic therapies. This meeting is intended to help professionals better understand the progress and ongoing challenges in this field and how we might meet them to ensure that precision diagnosis and, where available, targeted therapy is available to all children and young adults in the UK at diagnosis.
Day 1 - Monday 18th September 2017
0830 Registration open
0900 Poster set-up and viewing Fifty-four Poster presentations have been accepted
1000 Session 1 Introduction and Progress Update
1005 Welcome and Introduction CwC UK and Conference Chair
Dr Nick Goulden, Medical Director of Children with Cancer UK
Dr Olaf Heidenreich, Professor of Molecular Haematology, Wolfson Childhood Cancer Research Centre
1015 Update on Immunotherapy Professor Persis Amrolia View talk
Professor of Transplantation Immunology, UCL Institute of Child Health and
Consultant in Bone Marrow Transplant, Great Ormond Street Hospital for Children
1045 Children's Brain Tumour Drug Delivery Consortium Dr Ruman Rahman View talk
Assistant Professor of Molecular Neuro-Oncology,
Faculty of Medicine & Health Sciences, University of Nottingham, and
Deputy Chair of the International Children’s Brain Tumour Drug Delivery Consortium
1115-1145 Refreshments and comfort break. Poster presentations are available to view.
1145 Future CwC UK initiatives Alasdair Philips View talk
Trustee, Children with Cancer UK
An update on CwC UK's thinking on our priorities for research grant funding in the next few years
1200 What are the chief purported environmental & lifestyle causes of cancer in children & young people?
Professor Denis Henshaw View talk
Emeritus Professor of Human Radiation Effects, University of Bristol, and
Scientific Director, Children with Cancer UK
1230-1330 Lunch
1330 Session 2 Improving accuracy of diagnosis and risk stratification
Sub-classification of diseases in order to refine diagnosis, more accurately stratify prognosis and guide therapy has been a feature of paediatric oncology for over 50 years. New technologies have strengthened this effort, in some cases re-defining disease types and also allowing a more accurate diagnosis, with implications for therapy and causation. In addition the enhanced sensitivity provided by modern sequencing technologies means that liquid biopsy of circulating DNA rather than biopsy of bulk tumour is now a reality. These developments will be illustrated by four plenary presentations, covering medulloblastoma, acute myeloid leukaemia, rare haematological malignancies and rare solid tumours.
1330 Medulloblastoma Professor Steve Clifford View talk
Professor of Molecular Paediatric Oncology, Northern Institute for Cancer Research, Newcastle University
1400 Acute Myeloid Leukaemia Dr Phil Ancliff View talk
Consultant in Paediatric Haematology, Great Ormond Street Hospital for Children
1430 Rare Hematologic Malignancies Dr Anupama Rao View talk
Consultant in Paediatric Haematology, Great Ormond Street Hospital for Children
1500 Rare solid tumours Dr Tom Jacques View talk
Reader in Paediatric Neuropathology, UCL Institute of Child Health and
Histopathology Laboratory, Great Ormond Street Hospital for Children
1530-1600 Refreshments and comfort break
1600 Session 3 Integrating Genomics and Disease Modelling to Develop Targeted Therapies
Pre-clinical science holds the key to successfully harnessing the potential power of precision treatment. In this session three leading experts will illustrate approaches to discovery of new targets in acute leukaemia, brain tumours and neuroblastoma. They will focus on the importance of the development of preclinical models that replicate the changes seen in specific tumours as well as the need to study both diagnostic and relapse material. Each speaker will also show how an understanding the role of germline changes is beginning to allow us to understand the molecular steps involved in the development of cancer
1600 Acute Leukaemia Professor Olaf Heidenreich Newcastle View talk
Professor of Molecular Haematology, Wolfson Childhood Cancer Research Centre
Senior Lecturer for Paediatric Molecular Oncology and Childhood Cancer Theme Lead
Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle University Medical School
1630 Brain tumours Professor Amar Gajjar View talk
Chair of Pediatric Medicine, St Jude Children's Research Hospital, Mephis, USA
Co-Chair, Department of Oncology, St Jude Children's Research Hospital, Mephis, USA
Director, Neuro-Oncology Division and Brain Tumor Program, St Jude Children's Research Hospital.
1700 Solid Tumours/Neuroblastoma Professor Lou Chesler View talk
Team Leader Paediatric Solid Tumour Biology and Therapeutics, Institute of Cancer Research, London
Honorary Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust, London
1730-1800 Comfort break
1800 Session 4 Poster Session with pre-dinner reception
A call for Poster Abstracts of original research, for presentation at the meeting focusing, on the use of precision medicine in diagnostics and targeted therapy has been issued. Posters for all accepted abstracts will be display in this session which will be followed by the conference dinner.
1930 Children with Cancer UK Conference Dinner
The Conference Dinner is an integral part of this conference and is included in the price. It is at the same venue and will provide a good opportunity for networking with other researchers and clinicians.
Day 2 - Tuesday 19th September 2017
0900 Session 5 Current & Future Clinical Trials of Targeted Therapy
Proof of the value of precision medicine can only come from well-designed clinical trials. In this session four experts will discuss the challenges of moving from the preclinical to clinical application, the role of pharmacology and the challenges in designing trials of medicines targeted at genomic changes that may often occur at low frequency and in multiple tumour types.
0905 New therapeutic agents for early-phase trials Dr Darren Hargrave View talk
Consultant in Paediatric Oncology, Great Ormond Street Hospital, London
0930 Pharmacology Dr Gareth Veal View talk
Senior Lecturer in Pharmacology, Northern Institute for Cancer Research, Newcastle University
0955 Clinical Trial Design Professor Ruth Plummer View talk
Clinical Professor of Experimental Cancer Medicine, Northern Institute for Cancer Research, Medical School, Newcastle University
1020-1050 Refreshments and comfort break
1050-1130 Session 6 Short oral presentation of ten selected Posters
1130 Session 7 Presentation of UK Initiatives in Precision Medicine
This final session of the main meeting will discuss two important precision medicine initiatives funded in significant part by CwC UK – namely the SMPaeds and INSTINCT projects. Speakers will outline the aims and scope of these projects and how they can be accessed by individual clinical centres
1135 Precision medicine to reduce brain injury due to childhood brain tumours Professor David Walker View talk
Professor of Paediatric Oncology, Children’s Brain Tumour Research Centre, University of Nottingham and
Honorary Consultant in Paediatric Oncology, Nottingham Children’s Hospital
1200 SMPaeds Professor Lou Chesler View talk
Team Leader Paediatric Solid Tumour Biology and Therapeutics, Institute of Cancer Research, London
Honorary Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust, London
1225 INSTINCT Professor Steve Clifford View talk
Professor of Molecular Paediatric Oncology, Northern Institute for Cancer Research, Newcastle University
1250-1300 Short discussion on Section 7
1300-1400 Lunch (buffet), during which there is the option to attend:
A 20-minute presentation of Illumina's BaseSpace Variant Interpreter for Cancer Samples.
There will be a hands-on chance to experience this advanced software starting at 16:00 hrs.
Children with Cancer UK are offering this opportunity. We have no commercial involvement with Illumina.
1400 Session 8 Workshop Integrating genomics into studies of toxicity and quality of survival
1400-1545 Workshop led by:
Dr Rod Skinner, Consultant in Paediatric Oncology/Bone Marrow Transplantation, Newcastle NHS Hospitals Trust
Dr Sujith Samarasinghe, Consultant Paediatric Haematologist, Great Ormond Street Hospital, London
Much of the focus of the value of precision medicine has been on the development of new targeted therapies. Nevertheless, it is important to recognise that many children and young people will continue to receive standard therapy with its attendant short and long term side effects. This workshop aims to understand how the use of genetic technologies to predict both short and long term toxicities might be incorporated into clinical trials.
1545 Conference ends
1600-1700 Optional hands-on chance to experience Illumina's Basespace Interpreter Software
This page was last updated 5th September 2017 at 18:38
|
Visit the Children with Cancer UK website
